Real-world treatment outcomes and clinicopathologic determinants of response for patients with advanced thyroid cancer treated with first-line lenvatinib. This is an ASCO Meeting Abstract from the ...

1Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China.

The FDA granted full approval to Braftovi (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for adult patients with metastatic colorectal cancer (mCRC) harboring a BRAF ...

The FDA has granted traditional approval to encorafenib (Braftovi, Pfizer) in combination with cetuximab (Erbitux, Eli Lilly) and fluorouracil-based chemotherapy for treatment of adults with ...

Traditional FDA approval covers encorafenib plus cetuximab with fluorouracil-based chemotherapy for adult metastatic CRC with BRAF V600E mutations confirmed by an FDA-authorized test. BREAKWATER ...

Traditional approval was supported by BREAKWATER arm B showing PFS 12.8 vs 7.1 months (HR, 0.53) and OS 30.3 vs 15.1 months (HR, 0.49) versus control. Objective response improved with the ...

1Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College , Hangzhou, ...

Gorlin-Goltz syndrome (nevoid basal cell carcinoma syndrome) is a rare autosomal dominant tumor-predisposition disorder characterized by multiple basal cell carcinomas (BCCs), odontogenic keratocysts ...

Carolyn Gusoff has covered some of the most high profile news stories in the New York City area and is best known as a trusted, tenacious, consistent and caring voice of Long Island's concerns. For ...